Functional Target Validation for Alzheimer's Disease-Related Dementias
Funds phased research proving a newly identified Alzheimer's-related dementia target truly causes the disease process it's linked to.
A treatment can only be as good as the target it's aimed at, and right now the field has a shortage of well-validated ones. That is the barrier this notice is built to remove for Alzheimer's Disease-Related Dementias (ADRD) and other complex central nervous system disorders — translating a basic discovery into the clinic depends on how rigorously the target was validated, and on real confidence th…
Phased, milestone-gated validation of newly identified therapeutic target candidates for Alzheimer's Disease-Related Dementias, developing tools to modulate a candidate target and assess its physiological consequences in vitro and in vivo, then cross-validating the effect across multiple experimental modalities and collaborating laboratories.
Sign up free to see the funding breakdown
Sign up free to see the industries in scope
Sign up free to see the full eligibility
Sign up free to see how to apply
Sign up free to see what you submit
Sign up free to see how they score you
Sign up free to see the timeline
Sign up free to see where teams trip up